Ferring partners with Intralytix to develop bacteriophage treatments for conditions associated with the microbiome and drug-resistant bacteria
Ferring and IMAB sign licensing agreement granting IMAB exclusive rights in Asia to olamkicept for the treatment of autoimmune disease
Ferring receives EU approval for REKOVELLE® (follitropin delta)
Ferring Pharmaceuticals collaborates with MetaboGen AB on development of microbiome-based treatment for intrahepatic cholestasis of pregnancy (ICP)
Ferring International Center S.A.Ch. de la Vergognausaz 50CH-1162 Saint-PrexSwitzerlandTel: +41 58 301 00 00Fax: +41 58 301 00 10
Email for media enquiries only.For other queries, please see our Contact page.
Ferring International Center S.A.Ch. de la Vergognausaz 50 1162 Saint-PrexSwitzerland
Tel: +41 58 301 00 00Fax: +41 58 301 00 10
This global corporate website provides general information about the global Ferring Group. For information about Ferring or its products in a specific country, please select your country in the Global Locator. FERRING, the FERRING PHARMACEUTICALS logo and other Ferring product trade names are trademarks of Ferring B.V. save where indicated otherwise. ©2016 Ferring B.V.